Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group.

CONCLUSION: A provisional core domain set, presented for clinical trials in PMR, comprises acute phase markers, physical function, death, glucocorticoid-related adverse events, and development of giant cell arteritis. Measurement instruments are suggested that may cover each domain, but these require formal validation for clinical trials in PMR.
PMID: 26568595 [PubMed - as supplied by publisher]

Source: J Rheumatol - November 15, 2015 Category: Rheumatology Authors: Helliwell T, Brouwer E, Pease CT, Hughes R, Hill CL, Neill LM, Halls S, Simon LS, Mallen CD, Boers M, Kirwan JR, Mackie SL Tags: J Rheumatol Source Type: research